Bezlotoxumab denied as duplicate or overlapping therapy by Aetna?
If two medications appear duplicative on paper but serve different clinical purposes (e.g., short-acting vs long-acting), the appeal needs to spell out the clinical rationale for both.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Aetna typically requires
Aetna's specific coverage criteria for bezlotoxumab are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The Aetna angle on Bezlotoxumab
## Why Aetna Denied Bezlotoxumab as Duplicate Therapy
Aetna's duplicate-therapy denial means the reviewer concluded that another agent already in your current treatment plan serves the same clinical purpose as bezlotoxumab. This most commonly occurs when the record shows an active course of standard antibiotics for Clostridioides difficile infection without a clear explanation of why bezlotoxumab — which works through a distinct mechanism as a monoclonal antibody targeting a C. difficile toxin rather than acting as an antibiotic — is not redundant. Bezlotoxumab is not an antibiotic, so the premise of the denial is clinically questionable and almost always worth challenging.
## Why This Denial Is Appealable
Bezlotoxumab has a different mechanism and a different treatment goal than the antibiotic(s) used concurrently. It is specifically indicated to reduce the risk of recurrence, not to treat the active infection. A well-documented chart showing prior recurrence history and the prescriber's explanation of additive intent — not duplicative intent — is usually sufficient to overturn this denial.
## Federal Appeal Framework
- Internal appeal: ERISA-governed and ACA-compliant plans must provide a full-and-fair review (ERISA §503). Submit within the plan's stated deadline, typically 180 days from the denial notice.
- External review: After exhausting internal appeals (or on expedited track), you may request an Independent Review Organization (IRO) review under ACA §2719. The external-review window is generally open for approximately four months after the final internal denial.
- Expedited option: If your prescriber certifies that waiting through standard timelines would seriously jeopardize health, request expedited internal and external review simultaneously.
## Concrete Appeal Steps
1. Request the complete denial letter and Aetna's current published coverage policy for bezlotoxumab. 2. Obtain the FDA-approved prescribing information (Zinplava label) and locate the approved indication language verbatim. 3. Ask your prescriber to draft a medical-necessity letter explaining the distinct mechanism and the non-duplicative clinical role. 4. Compile all relevant records within the timeframe required by the plan.
## Documentation to Gather
- Diagnosis confirmation: Positive C. difficile laboratory results with dates.
- Recurrence history: Documentation of prior C. difficile episodes with dates, treatments, and outcomes.
- Current antibiotic regimen: Name, dates, and prescribing rationale to show it addresses active infection while bezlotoxumab addresses recurrence prevention.
- Prescriber letter: Explaining mechanism differentiation and why concurrent use is additive, not duplicative.
- Risk factors per chart: Any documented clinical factors that your prescriber and the FDA label identify as relevant to elevated recurrence risk.
## Criteria-Mapping Structure
Pull every criterion from (a) Aetna's published coverage/medical policy for bezlotoxumab and (b) the FDA-approved prescribing label. Create a two-column table: left column = the exact policy or label criterion; right column = the specific chart fact, lab result, or clinical note that satisfies it. For the duplicate-therapy criterion specifically, map the mechanism of bezlotoxumab against the mechanism of the concurrent antibiotic and demonstrate they are non-overlapping. Your prescriber's attestation that the combination is intentional and clinically necessary should appear as a direct quote from the medical-necessity letter.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →